• 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19
• A career in solving clinical-pathological conundrums: Heyde syndrome, anti-platelet factor 4 disorders, and microvascular limb ischemic necrosis
• A Case Report of Pulmonary Embolectomy Under Cardiopulmonary Bypass in a Patient with Intracranial Hemorrhage and History of Heparin-Induced Thrombocytopenia
• A Rare Case of Argatroban-Induced Anaphylaxis in a Patient With Intermediate-High Risk Pulmonary Embolism
• A retrospective analysis of the frequency of heparin-induced thrombocytopenia in the intensive care unit at a tertiary care center in Riyadh, Saudi Arabia
• A woman with eptifibatide (integrilin)-induced thrombocytopenia following treatment of a clot in her coronary artery: A case report and literature review
• Accuracy of Diagnosing Heparin-Induced Thrombocytopenia
• Acute coronary thrombosis due to heparin-induced thrombocytopenia following improved COVID-19 pneumonia: A case report
• Anti-PF4 antibodies and their relationship with COVID infection
• Anti-PF4 ELISA-Negative, SRA-Positive Heparin-Induced Thrombocytopenia
• Anti-PF4 positivity and platelet activation after Ad26.COV2·S vaccination in Brazil
• Anti-platelet factor 4 immunothrombotic syndromes
• Antibodies against Platelet Glycoproteins in Clinically Suspected VITT Patients
• Association between time of heparin exposure and platelets decline in patients with heparin induced thrombocytopenia
• Association of medical comorbidities in obese subjects diagnosed with heparin-induced thrombocytopenia
• Association of Metal Cations with the Anti-PF4/Heparin Antibody Response in Heparin-Induced Thrombocytopenia
• Association of Metal Cations with the Anti-PF4/Heparin Antibody Response in Heparin-Induced Thrombocytopenia
• Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?
• Between a rock and a hard place: anticoagulation management for ECMO
• Bivalirudin as a substitute for heparin in neurointervention for patients with heparin-induced thrombocytopenia
• Bolus-only bivalirudin for carotid endarterectomy in a patient with heparin-induced thrombocytopenia
• Cancer-associated thrombosis and bleeding
• Challenges in the Monitoring of Therapeutic Plasma Exchange during Acute Heparin-Induced Thrombocytopenia in Adults under ECMO
• Characterization of complexes of PF4 and heparins by size-exclusion chromatography coupled with multi-angle light scattering detector
• Characterization of the Benefits and Risks of Therapeutic Anticoagulation in Patients Admitted with Severe COVID-19 (CRITAC)
• Chemokine Oligomers and the Impact of Fondaparinux Binding
• Clinical and economic implications of false-positive heparin-induced thrombocytopenia immunoassays: utility of the 4T score
• Coagulation and platelet biology at the intersection of health and disease: illustrated capsules of the 11th Symposium on Hemostasis at the University of North Carolina
• Combination of 2 Quantitative Immunoassays and Clinical Score Algorithm to Reduce False-Negative Results in Heparin-Induced Thrombocytopenia: Prevalence Study of Mauriziano Hospital in Turin, Italy
• Complex management of pulmonary embolism in APLA syndrome: a case study of ECMO and bivalirudin utilization
• Dabigatran Etexilate Related Unilateral Adrenal Hemorrhage
• Decision-Making Error in Platelet Transfusion Caused by EDTA-Dependent Pseudothrombocytopenia: a Case Report and Literature Review
• Deep vein thrombosis: Implications of thromboprophylaxis after lower limb cast immobilisation
• Double Emergency: A Case of Concurrent Heparin-Induced Thrombocytopenia and Acute Promyelocytic Leukemia
• Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure
• Electronic alerts to improve management of heparin-induced thrombocytopenia
• Evaluating Diagnostic Algorithms for Heparin-Induced Thrombocytopenia using Two Combined Automated Rapid Immunoassays
• Evaluating the Use of Unfractionated Heparin with Intra-Aortic Balloon Counterpulsation
• Evaluation of Bivalirudin During Adult Extracorporeal Membrane Oxygenation: A Retrospective Characterization of Dosing, Efficacy and Bleeding
• Extensive reticular ecchymosis related to heparin-induced thrombocytopenia
• Flow cytometry vs conventional methods for the evaluation of anti-PF4/heparin antibodies: a single center study
• G6b-B antibody-based cis-acting platelet receptor inhibitors (CAPRIs) as a new family of anti-thrombotic therapeutics
• Haemorrhagic intracranial complications associated with vaccine-induced thrombocytopenia or central venous thrombosis after COVID-19 vaccination: postulated underlying mechanisms with literature and case review
• HEMA-Lysine-Based Cryogels for Highly Selective Heparin Neutralization
• Hematological features and alternate diagnoses in critically ill thrombotic antiphospholipid syndrome patients
• Heparin Induced Thrombocytopenia Testing
• Heparin-Induced Hemorrhagic Bullous Dermatosis: A Rare Complication of Unfractionated Heparin
• Heparin-Induced Thrombocytopenia
• Heparin-induced thrombocytopenia (and autoimmune heparin-induced thrombocytopenia): an illustrious review
• Heparin-Induced Thrombocytopenia (HIT) in the Direct Oral Anticoagulants (DOAC) Era
• Heparin-induced Thrombocytopenia (HIT) in the DOAC Era
• Heparin-induced thrombocytopenia after cardiac surgery. A single-center, retrospective cohort study
• Heparin-Induced Thrombocytopenia After Revascularization of Gustilo-Anderson Type IIIC Open Lower Leg Fracture: A Case Report of Subsequent Ischemic Limb Salvage Failure
• Heparin-induced thrombocytopenia in extracorporeal membrane oxygenation-supported patients: a systematic review and meta-analysis
• Heparin-Induced Thrombocytopenia in Patients Suffering Cardiogenic Shock
• Heparin-Induced Thrombocytopenia in Patients Suffering Cardiogenic Shock
• HEPARIN-INDUCED THROMBOCYTOPENIA SYNDROME AMONG HEMODIALYSIS PATIENTS AND DISEASE MANAGEMENT STRATEGY
• Heparin-induced Thrombocytopenia with Thrombosis in COVID-19 versus Vaccine-induced Immune Thrombocytopenia and Thrombosis in the United Kingdom
• Heparin-induced thrombocytopenia with very high antibody titer is associated with slower platelet recovery and higher risk of thrombosis
• Heparin-Induced Thrombocytopenia: A Case Report Four Years After the Initiation of Maintenance Hemodialysis
• High-Dose Immunoglobulin Therapy for Multiple Thromboembolism in Persisting Heparin-Induced Thrombocytopenia
• How We Interpret Thrombosis with Thrombocytopenia Syndrome?
• Immune-stealth VP28-conjugated heparin nanoparticles for enhanced and reversible anticoagulation
• Immunologic Effects of Heparin Associated With Hemodialysis: Focus on Heparin-Induced Thrombocytopenia
• Impact of Embedding a Venous Thromboembolism Risk Assessment Model in the Electronic Health Record Versus Usual Care: A Cluster-Randomized Trial
• In vitro Hemostatic Functions of Cold-Stored Platelets
• Interventional Therapy for Upper Extremity Phlegmasia Cerulea Dolens in a Patient With Heparin-Induced Thrombocytopenia: A Case Report
• Intracardiac Thrombus Associated With Heparin-Induced Thrombocytopenia in a Patient With Patent Foramen Ovale
• Key considerations in navigating ticagrelor's reported effect on heparin-induced thrombocytopenia functional assays in a landscape of limited data
• Laboratory approach for vaccine-induced thrombotic thrombocytopenia diagnosis in the Netherlands
• Limb Ischemic Necrosis Secondary to Microvascular Thrombosis: A Brief Historical Review
• Management of heparin-induced thrombocytopenia during extracorporeal membrane oxygenation support: a case of neutropenia caused by argatroban anticoagulation
• Molecular architecture and platelet-activating properties of small immune complexes assembled on heparin and platelet factor 4
• Multifaceted Cerebral Venous Thrombosis With Extensive Intra-cerebral Hemorrhage in a Young Man With Mitral Valve Replacement Due to Thrombosis and IgA Nephropathy: A Challenging Case Report From Saudi Arabia
• Multiple thromboses, including intracardiac thrombi, accompanied by HIT during ECMO successfully treated with NOACs: A case report
• New recommendations on cerebral venous and dural sinus thrombosis from the German consensus-based (S2k) guideline
• Online hemodiafiltration without calcium replacement using citrate as an anticoagulant and dialysis fluid with 3.5 mEq of post dilutional calcium in patients with heparin-induced thrombocytopenia: Report of 2 cases
• Outcomes of heparin-induced thrombocytopenia type II in aneurysmal subarachnoid hemorrhage patients: A US nationwide analysis
• Paradoxical Worsening of Cerebral Venous Sinus Thrombosis Due to Heparin-Induced Thrombocytopenia: A Case Report and Literature Review
• Plasma exchange and intravenous immunoglobulin for the peri-operative management of type 2 heparin-induced thrombocytopaenia in a patient requiring urgent surgery for critical limb ischaemia
• POCUS for Thrombus: Emphasizing the Importance of Initial Point-of-Care Ultrasound in the Management of Pulmonary Thromboembolism
• Proteomic profiling for biomarker discovery in heparin-induced thrombocytopenia
• Recurrent Venous Thromboembolism in Patients on Anticoagulation: An Update Based on the Revised AWMF S2k Guideline
• Repeated occurrence of severe hypotension associated with azithromycin infusion in a patient with fulminant myocarditis: a case report
• Results of an international survey of opinions on the definitions and treatments for heparin-induced thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology
• Structured benefit-risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer
• Temporal changes in biomarkers of neutrophil extracellular traps and NET-promoting autoantibodies following adenovirus-vectored, mRNA, and recombinant protein COVID-19 vaccination
• The Binding of the SARS-CoV-2 Spike Protein to Platelet Factor 4: A Proposed Mechanism for the Generation of Pathogenic Antibodies
• The Challenge of Managing a Primary Aortic Mural Thrombus: Outcomes and Technical Considerations
• The efficacy and safety of direct oral anticoagulants in the treatment of the acute phase of heparin-induced thrombocytopenia: A systematic review
• THE USE OF 1E12, A MONOCLONAL ANTI-PLATELET FACTOR 4 ANTIBODY TO IMPROVE THE DIAGNOSIS OF VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA
• The use of 1E12, a monoclonal anti-platelet factor 4 antibody, to improve the diagnosis of vaccine-induced immune thrombotic thrombocytopenia
• Therapeutic strategies in FcgammaIIA receptor-dependent thrombosis and thromboinflammation as seen in heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT)
• Thromboprophylaxis in hospitalized trauma patients: a systematic review and meta-analysis of implementation strategies
• To bite the hand that feeds you: A case of thrombotic microangiopathy due to Tiger snake bite
• Type II Heparin-Induced Thrombocytopenia Manifesting As Cardiac Arrest Following Intravenous Heparin Bolus During an Elective Procedure: A Case Report and Literature Review
• Unlocking the potential of fondaparinux: guideline for optimal usage and clinical suggestions (2023)
• Usefulness of bicarbonate-based Impella purge solution in a patient with heparin-induced thrombocytopenia: the first case report of long-term management in Japan
• Vaccine-Induced Immune Thrombotic Thrombocytopenia: Clinicopathologic Features and New Perspectives on Anti-PF4 Antibody-Mediated Disorders
• Zosyn-Induced Rapid Thrombocytopenia in a Patient With End-Stage Renal Disease and HIV: A Case Report